ANXA1 and metabolic disease: Last, there is evidence that Annexin A1, an endogenous molecule endowed with resolving/protecting action on tight junctions, may have therapeutic potential in restoring cerebrovascular damage and BBB disruption in neurodegenerative diseases and metabolic disorders (59).